Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion
Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.
Product Name : Tuznue
Product Type : Antibody
Upfront Cash : Inapplicable
July 31, 2024
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2022
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study met its primary endpoint (tpCR) and showed equivalent efficacy and comparable safety profile for Troika (HD201), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2 positive breast and metastatic gastric cancer.
Product Name : Tuznue
Product Type : Antibody
Upfront Cash : Inapplicable
March 14, 2022
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group
Deal Size : Inapplicable
Deal Type : Inapplicable
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Swedish Breast Cancer Group | Danish Breast Cancer Cooperative Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 27, 2018
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : Shanghai Zhongshan Hospital | Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2015
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : Shanghai Zhongshan Hospital | Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AGO Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2014
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AGO Germany
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Bayer AG | Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2014
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Bayer AG | Oregon Health and Science University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2013
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : National Health and Medical Research Council, Australia | Trans Tasman Radiation Oncology Group | European Organisation for Research and Treatment of Cancer | NCIC Clinical Trials Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2013
Lead Product(s) : Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable